Amyris Inc. (NASDAQ:AMRS) major shareholder (Mauritius) Pte Ltd Maxwell sold 509,779 shares of Amyris stock in a transaction on Thursday, November 17th. The stock was sold at an average price of $0.81, for a total transaction of $412,920.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

(Mauritius) Pte Ltd Maxwell also recently made the following trade(s):

  • On Tuesday, November 15th, (Mauritius) Pte Ltd Maxwell sold 648,342 shares of Amyris stock. The stock was sold at an average price of $0.81, for a total transaction of $525,157.02.
  • On Friday, November 11th, (Mauritius) Pte Ltd Maxwell sold 427,904 shares of Amyris stock. The stock was sold at an average price of $0.81, for a total transaction of $346,602.24.
  • On Tuesday, November 8th, (Mauritius) Pte Ltd Maxwell sold 333,811 shares of Amyris stock. The stock was sold at an average price of $0.82, for a total transaction of $273,725.02.
  • On Friday, November 4th, (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of Amyris stock. The stock was sold at an average price of $0.89, for a total transaction of $2,323,997.37.
  • On Monday, October 17th, (Mauritius) Pte Ltd Maxwell sold 2,300,000 shares of Amyris stock. The stock was sold at an average price of $0.83, for a total transaction of $1,909,000.00.

Shares of Amyris Inc. (NASDAQ:AMRS) traded down 0.1138% during midday trading on Friday, reaching $0.7897. 144,295 shares of the company were exchanged. The firm’s market capitalization is $196.79 million. The firm has a 50-day moving average of $0.84 and a 200 day moving average of $0.57. Amyris Inc. has a 52 week low of $0.31 and a 52 week high of $1.81.

Amyris (NASDAQ:AMRS) last issued its earnings results on Wednesday, November 2nd. The company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $33.61 million. The firm’s revenue was up 208.1% on a year-over-year basis. During the same period last year, the business earned ($0.23) EPS. On average, equities research analysts expect that Amyris Inc. will post ($0.25) EPS for the current year.

A number of equities analysts recently commented on the stock. Zacks Investment Research cut shares of Amyris from a “hold” rating to a “sell” rating in a research note on Monday, November 7th. Singular Research reaffirmed a “buy” rating and set a $2.80 price target on shares of Amyris in a research note on Wednesday, September 28th.

Several large investors have recently modified their holdings of AMRS. KBC Group NV boosted its stake in shares of Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares during the period. Vanguard Group Inc. boosted its stake in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Amyris during the first quarter worth approximately $269,000. Institutional investors and hedge funds own 35.75% of the company’s stock.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.